CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,379 | $42.79 | $59K | 55,639 |
| 2026-06-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,401 | $43.86 | $149K | 52,238 |
| 2026-06-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,238 | $44.75 | $55K | 51,000 |
| 2026-06-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −6,018 | 86,038 | ||
| 2026-06-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +5,000 | $2.48 | $12K | 30,000 |
| 2026-06-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −1,268 | $42.83 | $54K | 28,732 |
| 2026-06-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −2,599 | $43.87 | $114K | 26,133 |
| 2026-06-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −1,133 | $44.74 | $51K | 25,000 |
| 2026-06-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 121,268 | ||
| 2026-06-15 | ORBIMED ADVISORS LLC 10% owner | Sale | −9,086 | $45.02 | $409K | 245,728 |
| 2026-06-15 | ORBIMED ADVISORS LLC 10% owner | Sale | −272,322 | $45.02 | $12.3M | 7,388,902 |
| 2026-06-05 | Kunkel Lori Anne Director | Sale 10b5-1 | −7,779 | $34.28 | $267K | 54,105 |
| 2026-06-05 | Kunkel Lori Anne Director | Sale 10b5-1 | −1,867 | $35.36 | $66K | 52,238 |
| 2026-06-05 | Kunkel Lori Anne Director | Sale 10b5-1 | −354 | $35.82 | $13K | 51,884 |
| 2026-05-18 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +5,000 | $2.48 | $12K | 30,000 |
| 2026-05-18 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −3,475 | $39.53 | $137K | 26,525 |
| 2026-05-18 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −1,302 | $40.25 | $52K | 25,223 |
| 2026-05-18 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −223 | $41.21 | $9K | 25,000 |
| 2026-05-18 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 126,268 | ||
| 2026-04-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +5,000 | $2.48 | $12K | 30,000 |
Page 4 of 37 · 724 trades